This study is about a disease called Giant Cell Arteritis (GCA), which affects the blood vessels. Patients with GCA are taking a medicine called Tocilizumab (TCZ) to help them feel better. This research checks if it's safe to stop or reduce the dose of this medicine after patients have been well for a year without using steroids like prednisone.
The study involves three parts: a screening phase (up to 42 days) with health checks and blood tests, a treatment phase (18 months) where patients either stop or reduce TCZ doses, and a follow-up phase (19-30 months) with health checks every three months.
- Length: The study lasts for about 2.5 years.
- Visits: Regular clinic visits are required every two months during treatment and every three months during follow-up.
- Risks: There is a chance of GCA symptoms returning if the medicine dose is changed.
How understandable was the trial content above?
Hard to understand
Easy to understand